In this free webinar, explore lentiviral vector (LVV) applications in action, including early-stage cell therapy development, target validation and next-generation in-vivo CAR-T delivery, supported by real-world examples. Attendees will also learn about high-titer lentivirus production with scalable solutions designed to overcome challenges associated with complex constructs and hard-to-express payloads. The featured speaker will share insights into streamlined cell and gene therapy (CGT) workflows that use optimized LVV platforms to accelerate proof-of-concept studies and deliver high-titer lentivirus in just five business days.

TORONTO, Aug. 18, 2025 /PRNewswire/ -- Lentiviral vectors are indispensable tools in cell and gene therapy (CGT) research, due to their ability to stably integrate genetic material into both dividing and non-dividing cells. Their versatility makes them particularly well-suited for delivering a wide range of payloads — from classical gene addition constructs to complex multi-cistronic CARs, CRISPR-Cas components and regulatory circuits that enable precise expression control.

As CGT advances toward more sophisticated platforms, including in vivo delivery, lentiviral vectors are playing an increasingly critical role. This webinar will focus on the latest innovations driving the application of lentiviral systems in CGT therapy, particularly in vivo CAR-T therapies. Industry experts will share advanced strategies in vector design, packaging optimization and producer cell line engineering that significantly improve viral yields, enhance gene delivery in hard-to-transduce cells and ensure consistent, high-quality functional titers.

Register for this webinar to gain insights into lentivirus innovations driving breakthroughs in in vivo CAR-T and gene delivery.

Join Chuanxin Liu, PhD, Head of Viral Vector R&D, Life Science Group, GenScript Biotech Corporation, for the live webinar on Thursday, September 4, 2025, at 10am EDT (4pm CEST/EU-Central).

For more information, or to register for this event, visit High-Titer Lentivirus Solutions in 5 Days: Break Production Barriers for CGT.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

CONTACT:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-titer-lentivirus-solutions-in-5-days-break-production-barriers-for-cgt-upcoming-webinar-hosted-by-xtalks-302531185.html

SOURCE Xtalks